Adage Capital Partners GP L.L.C. Cuts Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Adage Capital Partners GP L.L.C. decreased its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 7.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 713,200 shares of the biotechnology company's stock after selling 54,743 shares during the quarter. Adage Capital Partners GP L.L.C. owned about 1.26% of Astria Therapeutics worth $6,376,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. KLP Kapitalforvaltning AS bought a new position in Astria Therapeutics during the fourth quarter worth about $41,000. Tower Research Capital LLC TRC boosted its holdings in shares of Astria Therapeutics by 109.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company's stock valued at $47,000 after purchasing an additional 2,766 shares in the last quarter. Teacher Retirement System of Texas acquired a new stake in shares of Astria Therapeutics in the 4th quarter valued at approximately $91,000. New York State Common Retirement Fund increased its position in Astria Therapeutics by 67.0% during the 4th quarter. New York State Common Retirement Fund now owns 10,720 shares of the biotechnology company's stock worth $96,000 after purchasing an additional 4,300 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Astria Therapeutics in the fourth quarter valued at approximately $107,000. 98.98% of the stock is owned by institutional investors.

Astria Therapeutics Price Performance

Shares of ATXS traded up $0.20 during midday trading on Friday, hitting $5.36. The stock had a trading volume of 408,704 shares, compared to its average volume of 365,826. Astria Therapeutics, Inc. has a 1 year low of $3.56 and a 1 year high of $12.92. The stock's 50 day moving average is $5.42 and its 200 day moving average is $7.95. The firm has a market cap of $302.49 million, a PE ratio of -2.56 and a beta of 0.68.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last released its earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.01. As a group, equities research analysts expect that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ATXS has been the topic of several recent analyst reports. Cantor Fitzgerald upgraded shares of Astria Therapeutics to a "strong-buy" rating in a report on Tuesday. JMP Securities started coverage on Astria Therapeutics in a research report on Friday, January 31st. They set an "outperform" rating and a $26.00 price target for the company. HC Wainwright reiterated a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a research note on Tuesday, March 11th. Wedbush reissued an "outperform" rating and issued a $28.00 price objective (up previously from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. Finally, Citizens Jmp upgraded shares of Astria Therapeutics to a "strong-buy" rating in a research report on Friday, January 31st. Five investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Astria Therapeutics has an average rating of "Buy" and an average target price of $30.00.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.